Phenotypic markers for a spectrum of colonic polyps and cancers. The malignancy potential ratio.
The purpose of this study was to determine if a panel of monoclonal antibodies could define phenotypic markers that could be used in risk assessment of a spectrum of colonic polyps and colon cancers. Using the ABC immunoperoxidase technique on formalin-fixed sections of surgical specimens, the following results were obtained: 1) Mab B72.3 demonstrated increased reactivity in villous lesions and cancers compared with hyperplastic polyps and tubular adenomas; 2) Mab anti-CAA demonstrated increased reactivity in polyps compared with colon cancers; and 3) using the two antibodies (Mab B72.3 and Mab anti-CAA), a malignancy ratio was obtained that determined malignancy risk for individual polyps. No hyperplastic polyp gave a positive ratio, but about 30 percent of villous lesions were positive. Over 50 percent of villous lesions greater than 2 cm in size had a positive ratio. The malignancy potential ratio may be a valuable marker in assessing risk of malignancy in an individual case.
Lundy
J
J
Department of Surgery, Winthrop University Hospital, Mineola, New York 11501.
Schuss
A
A
Lyubsky
S
S
Sadri
D
D
Stanick
D
D
D011125:Adenomatous Polyposis Coli / Q000276:immunology / Q000473:pathology; D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002471:Cell Transformation, Neoplastic; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology*; D003111:Colonic Polyps / Q000276:immunology / Q000473:pathology*; D006801:Humans; D007124:Immunoenzyme Techniques; D010641:Phenotype; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D014408:Biomarkers, Tumor